Alphabet-backed Isomorphic Labs is reportedly in discussions to raise approximately $5 billion in fresh funding, in a deal that could value the artificial intelligence-powered drug discovery company at around $50 billion. The potential financing, reported by Bloomberg on November 4, would make it one of the most highly valued companies operating at the intersection of artificial intelligence and biotechnology.
The proposed funding round has not been finalised, and its terms could change, according to people familiar with the discussions cited by Bloomberg. If completed at the reported size and valuation, the investment would represent a major increase in the company’s financial backing just months after it raised $2.1 billion in May 2026. The funding discussions also highlight growing investor interest in using AI to redesign how pharmaceutical companies discover and develop medicines.
Isomorphic Labs Could Raise Another $5 Billion
The reported $5 billion fundraising plan would value Isomorphic Labs at approximately $50 billion. The company is a subsidiary of Alphabet and was established as a spinout from Google DeepMind in 2021.
Bloomberg reported that the company is discussing the new financing with potential investors, but the identities of the investors and the proposed structure of the transaction have not been publicly disclosed.
The discussions follow an earlier report in October that Isomorphic Labs was exploring a funding round at a valuation of at least $40 billion, potentially reaching $50 billion. The latest report indicates that the company is considering raising around $5 billion at the upper end of that valuation range.
Isomorphic Labs has not publicly confirmed the reported fundraising discussions. The proposed investment should therefore be treated as a potential transaction rather than completed funding.
Company Raised $2.1 Billion in May 2026
The latest discussions come less than six months after Isomorphic Labs announced a $2.1 billion Series B funding round in May 2026.
The round was led by Thrive Capital and included participation from existing backers Alphabet and GV, alongside new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund.
The company said the capital would support the development of its AI drug-design engine, expansion of its drug candidate pipeline and recruitment of specialists in artificial intelligence, engineering, drug design and clinical development.
| Funding milestone | Details |
|---|---|
| Company founded | 2021 |
| Previous major funding round | $2.1 billion Series B |
| Previous round announced | May 12, 2026 |
| Lead investor | Thrive Capital |
| Reported new funding discussions | Approximately $5 billion |
| Potential valuation | Approximately $50 billion |
The proposed $5 billion investment would be substantially larger than the May financing round. However, until a transaction is announced, the company has not secured this additional capital.
How Isomorphic Labs Uses AI to Discover Drugs
Isomorphic Labs is attempting to apply artificial intelligence to one of the pharmaceutical industry’s most complex and expensive processes: discovering and designing new medicines.
Traditional drug discovery involves identifying a biological target associated with a disease, finding molecules that can interact with that target, testing their effectiveness and safety, and refining promising candidates through repeated experiments.
This process can take years and requires significant investment. Many potential drug candidates fail during development, including after entering clinical trials.
Isomorphic Labs is developing an integrated AI platform called the Isomorphic Labs Drug Design Engine (IsoDDE). The system combines computational models to help scientists understand biological systems, predict molecular interactions and design potential drug candidates.
The company’s technology builds on advances made by Google DeepMind, particularly AlphaFold, an AI system that predicts the three-dimensional structures of proteins. Understanding protein structures can help researchers investigate how biological molecules function and how medicines might interact with them.
However, protein structure prediction is only one part of drug development. Designing a promising molecule does not automatically establish that it will be safe, effective or suitable for human use.
Clinical Trials Remain a Critical Milestone
Despite its substantial funding and technological ambitions, Isomorphic Labs is still working to demonstrate that its AI-driven approach can produce successful medicines.
At the Bloomberg Tech conference in London on November 2, company president Max Jaderberg said its efforts to use AI for faster and more efficient drug discovery remained in preclinical stages. He described the company as being in its “first innings”.
CEO Demis Hassabis said in January 2026 that the company expected to move its first drug candidates into clinical trials by the end of the year.
Clinical trials are an essential stage in pharmaceutical development. They assess whether experimental medicines are safe and effective in people, following laboratory and other preclinical testing.
The distinction matters for investors. AI can help accelerate research, narrow down potential candidates and improve the efficiency of drug design, but commercial success ultimately depends on experimental validation, clinical outcomes and regulatory approval.
Partnerships With Major Pharmaceutical Companies
Isomorphic Labs has also established partnerships with established pharmaceutical companies, giving it opportunities to apply its technology to real drug discovery programmes.
Its partners include:
- Eli Lilly: A collaboration focused on using AI-powered approaches to discover new medicines.
- Novartis: A partnership involving the application of computational drug design to pharmaceutical research.
- Johnson & Johnson: Another pharmaceutical collaboration supporting the company’s drug discovery ambitions.
These partnerships are strategically important because pharmaceutical companies bring scientific expertise, research infrastructure and experience in clinical development.
For Isomorphic Labs, collaborations can provide access to drug discovery programmes and potential commercial opportunities. For pharmaceutical partners, AI-based drug design could offer additional ways to identify promising molecules and improve research productivity.
The financial terms and milestone structures of individual partnerships vary, so potential milestone payments should not be confused with guaranteed revenue.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
